Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 68169-68171 [E7-23363]

Download as PDF Federal Register / Vol. 72, No. 232 / Tuesday, December 4, 2007 / Notices This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Spotrias. Date: December 13–14, 2007. Time: 8 a.m. to 7 p.m. Agenda: To review and evaluate grant applications. Place: Mandarin Oriental Hotel, Washington, DC, 1330 Maryland Avenue, SW., Washington, DC 20024. Contact Person: Shanta Rajaram, PhD, Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20852, 301–435– 6033, rajarams@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: November 26, 2007 Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–5913 Filed 12–3–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Child Health and Human Development, Amended Notice of Meeting mstockstill on PROD1PC66 with NOTICES Notice is hereby given of a change in the meeting of the National Institute of Child Health and Human Development Special Emphasis Panel, December 4, 2007, 1 p.m. to December 4, 2007, 5 p.m., National Institutes of Health, 6100 Executive Boulevard, 5B01, Rockville, MD, 20852 which was published in the Federal Register on November 16, 2007, 72 FR 64658. The meeting will be held on December 5, 2007. The meeting is closed to the public. Dated: November 26, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–5914 Filed 12–3–07; 8:45 am] BILLING CODE 4140–01–M VerDate Aug<31>2005 17:38 Dec 03, 2007 Jkt 214001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Mental Health Draft Strategic Plan National Institute of Mental Health, NIH, HHS. ACTION: Notice. AGENCY: SUMMARY: The National Institute of Mental Health (NIMH) is developing a strategic plan for the next 3–5 years, and invites the public to provide comments on a draft of this plan. The draft plan will be publicly available through the NIMH Draft Strategic Plan Web page (http://www.nimh.nih.gov/about/ strategic-planning-reports/nimh-draftstrategic-plan.shtml) from November 20, 2007 through December 21, 2007. The public is invited to provide comments via the e-mail address or the postal address listed on the NIMH Draft Strategic Plan Web page. Background: NIMH is the lead Federal agency for research on mental and behavioral disorders and has as its mission to reduce the burden of these disorders through research on mind, brain, and behavior. The Institute’s goal is to generate research that will transform the prevention of and recovery from mental disorders. To inspire and support research that will make a difference for those living with mental illness, the Institute is developing a Strategic Plan to help direct this complex research effort and bring into sharper focus the methods, questions, and perspectives that will transform the diagnosis, treatment, and prevention of mental disorders, ultimately paving the way toward cures. NIMH’s draft Strategic Plan outlines several Strategic Objectives that will guide the research agenda for the Institute over the next several years. The public is invited to review this draft plan and provide comments between November 20, 2007 and December 21, 2007. The draft plan may be viewed at http://www.nimh.nih.gov/about/ strategic-planning-reports/nimh-draftstrategic-plan.shtml, and hard copies are available by calling 1–866–615–6464 (toll free) or by sending a letter requesting a copy (that includes your mailing address) to: National Institute of Mental Health, Attn: Draft Strategic Plan, 8280 Greensboro Drive, Suite 300, McLean, Virginia 22102. Request for Comments: The public is invited to provide comments on the draft Strategic Plan. Comments may be sent to the email address listed on the NIMH Strategic Planning Web page at PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 68169 http://www.nimh.nih.gov/about/ strategic-planning-reports/nimh-draftstrategic-plan.shtml, or sent to the postal address listed above. FOR FURTHER INFORMATION CONTACT: Additional information is posted on the NIMH Strategic Planning Web page, located at http://www.nimh.nih.gov/ about/strategic-planning-reports/nimhdraft-strategic-plan.shtml. Comments Due Date: Comments regarding the draft of NIMH’s strategic plan should be submitted via e-mail no later than December 21, 2007. Comments mailed to the above postal address must be postmarked by the same date. Dated: November 26, 2007. Thomas Insel, Director, National Institute of Mental Health, National Institutes of Health. [FR Doc. E7–23420 Filed 12–3–07; 8:45 am] BILLING CODE 4149–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies Substance Abuse and Mental Health Services Administration, HHS. ACTION: Notice. AGENCY: SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory’s certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines. If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter. E:\FR\FM\04DEN1.SGM 04DEN1 68170 Federal Register / Vol. 72, No. 232 / Tuesday, December 4, 2007 / Notices This notice is also available on the Internet at http:// www.workplace.samhsa.gov and http:// www.drugfreeworkplace.gov. Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, SAMHSA/CSAP, Room 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276– 2610 (fax). SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100– 71. Subpart C of the Mandatory Guidelines, ‘‘Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,’’ sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards. In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens: ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328– 7840 / 800–877–7016, (Formerly: Bayshore Clinical Laboratory). ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585–429–2264. Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770 / 888–290– 1150. Aegis Sciences Corporation, 345 Hill Ave., Nashville, TN 37210, 615–255– 2400, (Formerly: Aegis Analytical Laboratories, Inc.). Baptist Medical Center-Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center). Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215–2802, 800– 445–6917. mstockstill on PROD1PC66 with NOTICES FOR FURTHER INFORMATION CONTACT: VerDate Aug<31>2005 17:38 Dec 03, 2007 Jkt 214001 Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 239–561–8200 / 800–735–5416. Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229–671– 2281. DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974, 215–674–9310. Dynacare Kasper Medical Laboratories,* 10150–102 St., Suite 200, Edmonton, Alberta, Canada T5J 5E2, 780–451–3702 / 800–661–9876. ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662–236–2609. Gamma-Dynacare Medical Laboratories,* A Division of the Gamma-Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519– 679–1630. Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504–361–8989/800–433–3823, (Formerly: Laboratory Specialists, Inc.). Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond, VA 23236, 804–378–9130, (Formerly: Scientific Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.). Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713–856–8288 / 800–800–2387. Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908–526–2400 / 800–437–4986, (Formerly: Roche Biomedical Laboratories, Inc.). Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919– 572–6900 / 800–833–3984, (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group). Laboratory Corporation of America Holdings, 13112 Evening Creek Drive, Suite 100, San Diego, CA 92128, 858– 668–3710 / 800–882–7272, (Formerly: Poisonlab, Inc.). Laboratory Corporation of America Holdings, 550 17th Ave., Suite 300, Seattle, WA 98122, 206–923–7020 / 800–898–0180, (Formerly: DrugProof, Division of Dynacare/Laboratory of Pathology, LLC; Laboratory of Pathology of Seattle, Inc.; DrugProof, Division of Laboratory of Pathology of Seattle, Inc.). Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042 / 800–233– 6339, (Formerly: LabCorp Occupational PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 Testing Services, Inc.; MedExpress/ National Laboratory Center). LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927 / 800–873–8845, (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.). MAXXAM Analytics Inc.,* 6740 Campobello Road, Mississauga, ON, Canada L5N 2L8, 905–817–5700, (Formerly: NOVAMANN (Ontario), Inc.). MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651–636–7466 / 800–832–3244. MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295 / 800–950–5295. Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088. National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661–322–4250 / 800–350– 3515. One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774, (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory). Oregon Medical Laboratories, 123 International Way, Springfield, OR 97477, 541–341–8092. Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800–328–6942, (Formerly: Centinela Hospital Airport Toxicology Laboratory). Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991 / 800–541–7891x7. Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 858–643–5555. Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913–339–0372 / 800–821–3627. Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770–452–1590 / 800–729–6432, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories). Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631–4600 / 877–642–2216, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories). Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 866– 370–6699 / 818–989–2521, (Formerly: SmithKline Beecham Clinical Laboratories). E:\FR\FM\04DEN1.SGM 04DEN1 mstockstill on PROD1PC66 with NOTICES Federal Register / Vol. 72, No. 232 / Tuesday, December 4, 2007 / Notices S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505–727–6300 / 800–999–5227. South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574–234–4176 x276. Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602–438–8507 / 800–279–0027. Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517–364–7400, (Formerly: St. Lawrence Hospital & Healthcare System), St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405–272–7052. Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 65203, 573–882–1273. Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 33166, 305– 593–2260. US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George G. Meade, MD 20755–5235, 301–677–7085. The following laboratory will be voluntarily withdrawing from the HHS National Laboratory Certification Program on November 30, 2007: Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715–389– 3734 / 800–331–3734. *The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do. Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on April 13, 2004 (69 FR 19644). After receiving DOT VerDate Aug<31>2005 17:38 Dec 03, 2007 Jkt 214001 certification, the laboratory will be included in the monthly list of HHScertified laboratories and participate in the NLCP certification maintenance program. Elaine Parry, Acting Director, Office of Program Services, SAMHSA. [FR Doc. E7–23363 Filed 12–3–07; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HOMELAND SECURITY Coast Guard [USCG–2007–28578] Collection of Information Under Review by Office of Management and Budget: OMB Control Number: 1625– 0089 Coast Guard, DHS. Thirty-day notice requesting comments. AGENCY: ACTION: SUMMARY: In compliance with the Paperwork Reduction Act of 1995, this request for comments announces that the U.S. Coast Guard is forwarding one Information Collection Request (ICR), abstracted below, to the Office of Information and Regulatory Affairs (OIRA) of the Office of Management and Budget (OMB) requesting reinstatement, with change, of a previously-approved collection of information: 1625–0089, National Recreation Boating Survey. Our ICR describes the information we seek to collect from the public. Review and comments by OIRA ensure we only impose paperwork burdens commensurate with our performance of duties. DATES: Please submit comments on or before January 3, 2008. ADDRESSES: To make sure your comments and related material do not enter the Coast Guard docket [USCG– 2007–29070] or are received by OIRA more than once, please submit them by only one of the following means: (1) Electronic submission. (a) To Coast Guard docket at http:// www.regulations.gov. (b) To OIRA by e-mail to: nlesser@omb.eop.gov. (2) Mail or Hand delivery. (a) To Docket Management Facility (M–30), U.S. Department of Transportation, West Building Ground Floor, Room W12–140, 1200 New Jersey Avenue, SE., Washington, DC 20590–0001. Hand deliver between the hours of 9 a.m. and 5 p.m., Monday through Friday, except PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 68171 Federal holidays. The telephone number is 202–366–9329. (b) To OIRA, 725 17th Street, NW., Washington, DC 20503, to the attention of the Desk Officer for the Coast Guard. (3) Fax. (a) To Docket Management Facility at 202–493–2251. (b) To OIRA at 202–395–6566. To ensure your comments are received in time, mark the fax to the attention of Mr. Nathan Lesser, Desk officer for the Coast Guard. The Docket Management Facility maintains the public docket for this notice. Comments and material received from the public, as well as documents mentioned in this notice as being available in the docket, will become part of this docket and will be available for inspection or copying at room W12–140 on the West Building Ground Floor, 1200 New Jersey Avenue, SE., Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays. You may also find this docket on the Internet at http:// www.regulations.gov. A copy of the complete ICR is available through this docket on the Internet at http://www.regulations.gov. Additionally, copies are available from Commandant (CG–611), U.S. Coast Guard Headquarters, (Attn: Mr. Arthur Requina), 2100 2nd Street, SW., Washington, DC 20593–0001. The telephone number is (202) 475–3523. FOR FURTHER INFORMATION CONTACT: Mr. Arthur Requina, Office of Information Management, telephone (202) 475–3523 or fax (202) 475–3929, for questions on these documents. Contact Ms. Renee V. Wright, Program Manager, Docket Operations, (202) 366–9826, for questions on the docket. SUPPLEMENTARY INFORMATION: The Coast Guard invites comments on the proposed collection of information to determine if it is necessary in the proper performance of Departmental functions. In particular, the Coast Guard would appreciate comments addressing: (1) The practical utility of the collection; (2) the accuracy of the estimated burden of the collection; (3) ways to enhance the quality, utility, and clarity of information subject to the collection; and (4) ways to minimize the burden of collection on respondents, including the use of automated collection techniques or other forms of information technology. Comments to the FDMS or OIRA must contain the OMB Control Number of the ICR addressed. Comments must contain the docket number of this request, [USCG 2007–28578]. For your comments to OIRA to be considered, it is best if they are received on or before the January 3, 2008. E:\FR\FM\04DEN1.SGM 04DEN1

Agencies

[Federal Register Volume 72, Number 232 (Tuesday, December 4, 2007)]
[Notices]
[Pages 68169-68171]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-23363]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Current List of Laboratories Which Meet Minimum Standards To 
Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Department of Health and Human Services (HHS) notifies 
Federal agencies of the laboratories currently certified to meet the 
standards of Subpart C of the Mandatory Guidelines for Federal 
Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory 
Guidelines were first published in the Federal Register on April 11, 
1988 (53 FR 11970), and subsequently revised in the Federal Register on 
June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on 
April 13, 2004 (69 FR 19644).
    A notice listing all currently certified laboratories is published 
in the Federal Register during the first week of each month. If any 
laboratory's certification is suspended or revoked, the laboratory will 
be omitted from subsequent lists until such time as it is restored to 
full certification under the Mandatory Guidelines.
    If any laboratory has withdrawn from the HHS National Laboratory 
Certification Program (NLCP) during the past month, it will be listed 
at the end, and will be omitted from the monthly listing thereafter.

[[Page 68170]]

    This notice is also available on the Internet at http://
www.workplace.samhsa.gov and http://www.drugfreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, 
Division of Workplace Programs, SAMHSA/CSAP, Room 2-1035, 1 Choke 
Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-
2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in 
accordance with Executive Order 12564 and section 503 of Pub. L. 100-
71. Subpart C of the Mandatory Guidelines, ``Certification of 
Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets 
strict standards that laboratories must meet in order to conduct drug 
and specimen validity tests on urine specimens for Federal agencies. To 
become certified, an applicant laboratory must undergo three rounds of 
performance testing plus an on-site inspection. To maintain that 
certification, a laboratory must participate in a quarterly performance 
testing program plus undergo periodic, on-site inspections.
    Laboratories which claim to be in the applicant stage of 
certification are not to be considered as meeting the minimum 
requirements described in the HHS Mandatory Guidelines. A laboratory 
must have its letter of certification from HHS/SAMHSA (formerly: HHS/
NIDA) which attests that it has met minimum standards.
    In accordance with Subpart C of the Mandatory Guidelines dated 
April 13, 2004 (69 FR 19644), the following laboratories meet the 
minimum standards to conduct drug and specimen validity tests on urine 
specimens:
    ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-
328-7840 / 800-877-7016, (Formerly: Bayshore Clinical Laboratory).
    ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 
14624, 585-429-2264.
    Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, 
Memphis, TN 38118, 901-794-5770 / 888-290-1150.
    Aegis Sciences Corporation, 345 Hill Ave., Nashville, TN 37210, 
615-255-2400, (Formerly: Aegis Analytical Laboratories, Inc.).
    Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7, 
Little Rock, AR 72205-7299, 501-202-2783, (Formerly: Forensic 
Toxicology Laboratory Baptist Medical Center).
    Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802, 
800-445-6917.
    Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort 
Myers, FL 33913, 239-561-8200 / 800-735-5416.
    Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 
229-671-2281.
    DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 
18974,
    215-674-9310.
    Dynacare Kasper Medical Laboratories,* 10150-102 St., Suite 200, 
Edmonton, Alberta, Canada T5J 5E2, 780-451-3702 / 800-661-9876.
    ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 
38655, 662-236-2609.
    Gamma-Dynacare Medical Laboratories,* A Division of the Gamma-
Dynacare Laboratory Partnership, 245 Pall Mall Street, London, ONT, 
Canada N6A 1P4, 519-679-1630.
    Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 
70053, 504-361-8989/800-433-3823, (Formerly: Laboratory Specialists, 
Inc.).
    Kroll Laboratory Specialists, Inc., 450 Southlake Blvd., Richmond, 
VA 23236, 804-378-9130, (Formerly: Scientific Testing Laboratories, 
Inc.; Kroll Scientific Testing Laboratories, Inc.).
    Laboratory Corporation of America Holdings, 7207 N. Gessner Road, 
Houston, TX 77040, 713-856-8288 / 800-800-2387.
    Laboratory Corporation of America Holdings, 69 First Ave., Raritan, 
NJ 08869, 908-526-2400 / 800-437-4986, (Formerly: Roche Biomedical 
Laboratories, Inc.).
    Laboratory Corporation of America Holdings, 1904 Alexander Drive, 
Research Triangle Park, NC 27709, 919-572-6900 / 800-833-3984, 
(Formerly: LabCorp Occupational Testing Services, Inc., CompuChem 
Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche 
Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of 
the Roche Group).
    Laboratory Corporation of America Holdings, 13112 Evening Creek 
Drive, Suite 100, San Diego, CA 92128, 858-668-3710 / 800-882-7272, 
(Formerly: Poisonlab, Inc.).
    Laboratory Corporation of America Holdings, 550 17th Ave., Suite 
300, Seattle, WA 98122, 206-923-7020 / 800-898-0180, (Formerly: 
DrugProof, Division of Dynacare/Laboratory of Pathology, LLC; 
Laboratory of Pathology of Seattle, Inc.; DrugProof, Division of 
Laboratory of Pathology of Seattle, Inc.).
    Laboratory Corporation of America Holdings, 1120 Main Street, 
Southaven, MS 38671, 866-827-8042 / 800-233-6339, (Formerly: LabCorp 
Occupational Testing Services, Inc.; MedExpress/National Laboratory 
Center).
    LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, 
KS 66219, 913-888-3927 / 800-873-8845, (Formerly: Quest Diagnostics 
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division 
of LabOne, Inc.).
    MAXXAM Analytics Inc.,* 6740 Campobello Road, Mississauga, ON, 
Canada L5N 2L8, 905-817-5700, (Formerly: NOVAMANN (Ontario), Inc.).
    MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 
55112, 651-636-7466 / 800-832-3244.
    MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 
97232, 503-413-5295 / 800-950-5295.
    Minneapolis Veterans Affairs Medical Center, Forensic Toxicology 
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
    National Toxicology Laboratories, Inc., 1100 California Ave., 
Bakersfield, CA 93304, 661-322-4250 / 800-350-3515.
    One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, 
Pasadena, TX 77504, 888-747-3774, (Formerly: University of Texas 
Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology 
Laboratory).
    Oregon Medical Laboratories, 123 International Way, Springfield, OR 
97477, 541-341-8092.
    Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology 
Laboratory).
    Pathology Associates Medical Laboratories, 110 West Cliff Dr., 
Spokane, WA 99204, 509-755-8991 / 800-541-7891x7.
    Phamatech, Inc., 10151 Barnes Canyon Road, San Diego, CA 92121, 
858-643-5555.
    Physicians Reference Laboratory, 7800 West 110th St., Overland 
Park, KS 66210, 913-339-0372 / 800-821-3627.
    Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 
30340, 770-452-1590 / 800-729-6432, (Formerly: SmithKline Beecham 
Clinical Laboratories; SmithKline Bio-Science Laboratories).
    Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 
19403, 610-631-4600 / 877-642-2216, (Formerly: SmithKline Beecham 
Clinical Laboratories; SmithKline Bio-Science Laboratories).
    Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 
91405, 866-370-6699 / 818-989-2521, (Formerly: SmithKline Beecham 
Clinical Laboratories).

[[Page 68171]]

    S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 
87109, 505-727-6300 / 800-999-5227.
    South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South 
Bend, IN 46601, 574-234-4176 x276.
    Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, 
Phoenix, AZ 85040, 602-438-8507 / 800-279-0027.
    Sparrow Health System, Toxicology Testing Center, St. Lawrence 
Campus, 1210 W. Saginaw, Lansing, MI 48915, 517-364-7400, (Formerly: 
St. Lawrence Hospital & Healthcare System),
    St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., 
Oklahoma City, OK 73101, 405-272-7052.
    Toxicology & Drug Monitoring Laboratory, University of Missouri 
Hospital & Clinics, 301 Business Loop 70 West, Suite 208, Columbia, MO 
65203, 573-882-1273.
    Toxicology Testing Service, Inc., 5426 N.W. 79th Ave., Miami, FL 
33166, 305-593-2260.
    US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson 
St., Fort George G. Meade, MD 20755-5235, 301-677-7085.
    The following laboratory will be voluntarily withdrawing from the 
HHS National Laboratory Certification Program on November 30, 2007:
    Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North 
Oak Ave., Marshfield, WI 54449, 715-389-3734 / 800-331-3734.
    *The Standards Council of Canada (SCC) voted to end its Laboratory 
Accreditation Program for Substance Abuse (LAPSA) effective May 12, 
1998. Laboratories certified through that program were accredited to 
conduct forensic urine drug testing as required by U.S. Department of 
Transportation (DOT) regulations. As of that date, the certification of 
those accredited Canadian laboratories will continue under DOT 
authority. The responsibility for conducting quarterly performance 
testing plus periodic on-site inspections of those LAPSA-accredited 
laboratories was transferred to the U.S. HHS, with the HHS' NLCP 
contractor continuing to have an active role in the performance testing 
and laboratory inspection processes. Other Canadian laboratories 
wishing to be considered for the NLCP may apply directly to the NLCP 
contractor just as U.S. laboratories do.
    Upon finding a Canadian laboratory to be qualified, HHS will 
recommend that DOT certify the laboratory (Federal Register, July 16, 
1996) as meeting the minimum standards of the Mandatory Guidelines 
published in the Federal Register on April 13, 2004 (69 FR 19644). 
After receiving DOT certification, the laboratory will be included in 
the monthly list of HHS-certified laboratories and participate in the 
NLCP certification maintenance program.

Elaine Parry,
Acting Director, Office of Program Services, SAMHSA.
[FR Doc. E7-23363 Filed 12-3-07; 8:45 am]
BILLING CODE 4162-20-P